Sitagliptin vs Avanafil: side-by-side comparison
Sitagliptin (DPP-4 inhibitor) and Avanafil (Phosphodiesterase type 5 (PDE5) inhibitor) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Sitagliptin | Avanafil |
|---|---|---|
| Therapeutic class | DPP-4 inhibitor | Phosphodiesterase type 5 (PDE5) inhibitor |
| CAS | 486460-32-6 | 330784-47-9 |
| ATC | A10BH01 | G04BE10 |
| Molecular weight | 407.31 g/mol | 483.95 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Sitagliptin and Avanafil share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Sitagliptin acts by a different mechanism than Avanafil, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Sitagliptin: La sitagliptine inhibe de façon réversible la DPP-4, sérine protéase responsable de la dégradation rapide du glucagon-like peptide 1 (GLP-1) et du polypeptide insulinotrope glucose-dépendant (GIP). Avanafil: L'avanafil inhibe sélectivement la phosphodiestérase de type 5 dans le corps caverneux, ce qui augmente le GMP cyclique et amplifie la vasodilatation médiée par le monoxyde d'azote en réponse à la stimulation sexuelle.
Indications compared
Sitagliptin: La sitagliptine est autorisée chez l'adulte atteint de diabète de type 2, seule ou en association à d'autres antidiabétiques, pour améliorer le contrôle glycémique. Avanafil: L'avanafil est autorisé dans la dysfonction érectile chez l'homme adulte.
Safety profile
Sitagliptin: La sitagliptine est généralement bien tolérée. Avanafil: Les effets indésirables les plus fréquents sont les céphalées, les bouffées vasomotrices, la congestion nasale et les douleurs dorsales — typiques de la classe des inhibiteurs de la PDE5, mais généralement moins fréquent…
Questions fréquentes
Is Sitagliptin better than Avanafil? ▾
Sitagliptin and Avanafil are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Sitagliptin and Avanafil be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Sitagliptin
Products with Avanafil
Les informations publiées sur ce site sont fournies à titre documentaire et pédagogique. Elles ne remplacent pas l'avis d'un professionnel de santé qualifié.